NCT01849939View on ClinicalTrials.gov

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

PHASE2UnknownINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Chronic Lymphocytic LeukemiaLymphocytic Lymphoma
Interventions
DRUG

Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)

Trial Locations (1)

63003

RECRUITING

CHU Clermont-Ferrand, Clermont-Ferrand

Sponsors

Collaborators (1)

Pierre Fabre Laboratories
All Listed Sponsors
collaborator

Pierre Fabre Laboratories

INDUSTRY

lead

University Hospital, Clermont-Ferrand

OTHER